Imaging and dosimetric characteristics of Cu.

In recent years the use of beta-emitting radiopharmaceuticals for cancer therapy has expanded rapidly following development of therapeutics for neuroendocrine tumors, prostate cancer, and other oncologic malignancies. One emerging beta-emitting radioisotope of interest for therapy is Cu (t: 2.6 d) due to its chemical equivalency with the widely-established positron-emitting isotope Cu (t: 12.